| Catalog No. | DB949018 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 97.28 ng/mL |
|---|
| Range | 125 - 4,000 ng/mL |
|---|
| Accession | P27037 & Q13705 |
|---|
| Applications | ELISA |
|---|
| Detection method | Colorimetric |
|---|
| Assay type | Quantitative |
|---|
| Recovery | 80-120% |
|---|
| Shipping | 2-8 ℃ |
|---|
| Stability and Storage | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃. |
|---|
| Specifications | Bimagrumab |
|---|
| Alternate Names | BYM338, CAS: 1356922-05-8 |
|---|
| Background | Bimagrumab is a monoclonal anti-ActRIIA/IIB antibody that targets ActRIIA and ActRIIB simultaneously. Native ActRIIA and ActRIIB are both mediators of signaling from several TGFβ superfamily members such as activins, myostatin, and GDF11. Hence, pan-blockade by Bimagrumab achieves greater effect than a monoclonal antibody against either receptor alone, i.e. monotherapy with anti-ActRIIA antibody or anti-ActRIIB antibody. Bimagrumab has been explored as a therapy for sporadic inclusion body myositis, primary sarcopenia, and muscle wasting associated with chronic obstructive pulmonary disease. |
|---|
| Note | For Research Use Only. |
|---|
